|
EARLY VIRAL RESPONSE
TO CPG 10101, IN COMBINATION WITH
PEGYLATED INTERFERON AND/OR RIBAVIRIN,
IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS
WITH PRIOR RELAPSE RESPONSE
J G McHutchison. Abstract 730
|
|
INTERIM RESULTS OF A
MULTIPLE ASCENDING DOSE
STUDY OF R1626, A NOVEL
NUCLEOSIDE ANALOG
TARGETING HCV POLYMERASE IN
CHRONIC HCV PATIENTS
S Roberts. Abstract 731.
|
|
INTERIM (WEEK 12)
PHASE 2B VIROLOGICAL EFFICACY AND SAFETY
RESULTS OF ALBUMIN INTERFERON ALFA-2B
COMBINED WITH RIBAVIRIN IN GENOTYPE 1
CHRONIC HEPATITIS C INFECTION
S Zeuzem. Abstract 733.
|
|
PEGINTERFERON ALFA-2A (PEGASYS)
PLUS RIBAVIRIN (COPEGUS)
FOR 16
OR 24 WEEKS IN PATIENTS WITH
HCV GENOTYPE 2 OR 3. FINAL
RESULTS OF THE ACCELERATE
TRIAL
M L Shiffman. Abstract
734.
|
EARLY CLEARANCE OF HCV
RNA WITH VALOPICITABINE (NM283) PLUS PEG-INTERFERON
IN TREATMENT-NAÏVE PATIENTS WITH HCV-1
INFECTION: FIRST RESULTS FROM A PHASE IIB
TRIAL
D Dieterich. Abstract 736.
|
|
INITIAL RESULTS OF A 14-DAY
STUDY OF THE HEPATITIS C
VIRUS INHIBITOR PROTEASE
VX-950, IN COMBINATION WITH
PEGINTERFERON-ALFA-2A
HW Reesink. Abstract 737.
|
|
SUSTAINED VIROLOGIC
RESPONSE (SVR) TO INTERFERON-ALFA-2B+/-
RIBAVIRIN THERAPY AT 6 MONTHS RELIABLY
PREDICTS LONG-TERM CLEARANCE OF HCV AT 5-YEAR
FOLLOW UP
J G McHutchison. Abstract 744.
|
|
A ONE
YEAR RANDOMIZED, PLACEBO-CONTROLLED,
DOUBLE-BLIND TRIAL OF
ROSIGLITAZONE IN NON
ALCOHOLIC STEATOHEPATITIS:
RESULTS OF THE FLIRT PILOT
TRIAL
V Ratziu. Abstract 738.
|
|
EFFICACY AND SAFETY OF
ELTROMBOPAG, AN ORAL PLATELET GROWTH
FACTOR, IN SUBJECTS WITH HCV ASSOCIATED
THROMBOCYTOPENIA: PRELIMINARY RESULTS FROM A
PHASE II DOSE-RANGING STUDY
J G McHutchison. Abstract 745.
|
|
PRECLINICAL CHARACTERISTICS
OF ITMN-B, AN ORALLY
ACTIVE INHIBITOR OF THE HCV
NS3/4A PROTEASE
NOMINATED FOR PRECLINICAL
DEVELOPMENT
S D Seiwert. Abstract
750.
|
Treatment for
Chronic Hepatitis B
|
|
THE
MAJORITY OF PATIENTS WITH
HBEAG-NEGATIVE CHRONIC
HEPATITIS B TREATED WITH
PEGINTERFERON ALFA-2A (40KD)
[PEGASYS®] SUSTAIN
RESPONSES 2 YEARS POST-TREATMENT
P Marcellin. Abstract 743.
|
|
EMERGENCE OF DUAL-RESISTANCE
HBV MUTATIONS TO ADEFOVIR-DIPIVOXIL AND
LAMIVUDINE IN A HEPATITIS B PATIENT WITH
COMBINATION THERAPY FOR ADEFOVIR-RESISTANCE
SY Kwon. Abstract 740.
|
|
EFFECT
OF CORE PROMOTER/PRECORE
MUTATION PATTERN AND EARLY
VIROLOGIC RESPONSE ON
EFFICACY OUTCOMES WITH
TELBIVUDINE IN HBEAG-NEGATIVE
CHRONIC HEPATITIS B
N Naoumov. Abstract 747.
|
|
SAFETY, TOLERABILITY
AND ANTIVIRAL ACTIVITY OF PRADEFOVIR
MESYLATE IN PATIENTS WITH CHRONIC
HEPATITIS B VIRUS INFECTION: 48-WEEK
ANALYSIS OF A PHASE 2 STUDY
K S Lee. Abstract 741.
|
|
A
NOVEL PRIMEBOOST THERAPEUTIC
VACCINE INDUCES
SUSTAINED SEROCONVERSION AT
52 WEEKS IN PATIENTS WITH
HBEAG+ CHRONIC HEPATITIS B:
A PHASE IIA CLINICAL TRIAL
J Schneider. Abstract
749.
|
|
|
